Argenx

Argenx, a pharmaceutical preparation manufacturing company headquartered in the Netherlands, has reported its carbon emissions for recent years. In 2024, the company's total emissions reached approximately 231,769,000 kg CO2e. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. Scope 1 emissions accounted for about 3,788,000 kg CO2e, while Scope 2 emissions were approximately 534,000 kg CO2e (market-based). Scope 3 emissions constituted the majority, at approximately 227,447,000 kg CO2e. Within Scope 3, purchased goods and services were the largest contributor, at approximately 183,781,000 kg CO2e, followed by upstream transportation and distribution at approximately 24,556,000 kg CO2e, and business travel at approximately 13,340,000 kg CO2e.

In 2023, Argenx's total emissions were approximately 433,353,000 kg CO2e. Scope 1 emissions for that year were about 378,000 kg CO2e, with Scope 2 emissions at approximately 189,000 kg CO2e (market-based). Scope 3 emissions were substantial at approximately 432,786,000 kg CO2e. The primary driver within Scope 3 in 2023 was purchased goods and services, contributing approximately 378,956,000 kg CO2e.

Argenx has not publicly disclosed specific reduction targets or participation in initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge in the provided information. Their climate commitments and detailed reduction strategies are not specified.